Active surveillance of candidemia in children from latin america: A key requirement for improving disease outcome

Pediatric Infectious Disease Journal

Volumn 33, Issue 2, 2014, Pages

  Santolaya, Maria E ^a   Alvarado, Tito ^b   Queiroz Telles, Flavio ^c   Colombo, Arnaldo L ^d   Zurita, Jeanette ^e   Tiraboschi, Iris N ^f   Cortes, Jorge Alberto ^g   Thompson, Luis ^h   Guzman, Manuel ⁱ   Sifuentes, Jose ^j   Echevarría, Juan I ^k   Nucci, Marcio ^l  

^a UNIVERSITY OF CHILE   (Chile)

^b Hospital Escuela   (Honduras)

^c FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^d FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^e PONTIFICIA UNIVERSIDAD CATÓLICA DEL ECUADOR   (Ecuador)

^f HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

^g UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^h UNIVERSIDAD DEL DESARROLLO   (Chile)

ⁱ Hospital Vargas de Caracas   (Venezuela)

^j INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^k UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^l FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

more..

Author keywords

Candidemia; children; epidemiology; Latin America

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; CORTICOSTEROID;

ADOLESCENT; ARTICLE; ARTIFICIAL VENTILATION; CANDIDA ALBICANS; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CHILD; CONTROLLED STUDY; FEMALE; HOSPITAL; HUMAN; INCIDENCE; INFANT; INFECTION RISK; INTENSIVE CARE UNIT; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUROLOGIC DISEASE; NEUTROPENIA; NEWBORN; NONHUMAN; PARENTERAL NUTRITION; PREMATURITY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESPIRATORY TRACT DISEASE; SCHOOL CHILD; SOUTH AND CENTRAL AMERICA; SURVIVAL; SURVIVAL RATE;

ADOLESCENT; ANTIFUNGAL AGENTS; CANDIDA; CANDIDEMIA; CHILD; CHILD, PRESCHOOL; FEMALE; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; INTENSIVE CARE UNITS; LATIN AMERICA; MALE; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84893002756     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000039     Document Type: Article

References (37)

1. Zaoutis TE, Argon J, Chu J, et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States a propensity analysis. Clin Infect Dis. 2005;411232-1239
2. Wisplinghoff H, Seifert H, Tallent SM, et al. Nosocomial bloodstream infections in pediatric patients in United States hospitals epidemiology, clinical features and susceptibilities. Pediatr Infect Dis J. 2003;22686-691
3. Raymond J, Aujard Y. Nosocomial infections in pediatric patients a European, multicenter prospective study. European Study Group. Infect Control Hosp Epidemiol. 2000;21260-263
4. Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates the experience of the NICHD Neonatal Research Network. Pediatrics. 2002;110(2 pt 1)285-291
5. Manzoni P, Farina D, Leonessa M, et al. Risk factors for progression to invasive fungal infection in preterm neonates with fungal colonization. Pediatrics. 2006;1182359-2364
6. Benjamin DK Jr, Stoll BJ, Fanaroff AA, et al.; National Institute of Child Health and Human Development Neonatal Research Network. Neonatal candidiasis among extremely low birth weight infants risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics. 2006;11784-92
7. Kaufman DA, Manzoni P. Strategies to prevent invasive candidal infection in extremely preterm infants. Clin Perinatol. 2010;37611-628
8. Paganini H, Rodriguez Brieshcke T, Santos P, et al. Risk factors for nosocomial candidaemia a case-control study in children. J Hosp Infect. 2002;50304-308
9. Villarroel M, Avilés CL, Silva P, et al. Risk factors associated with invasive fungal disease in children with cancer and febrile neutropenia a prospective multicenter evaluation. Pediatr Infect Dis J. 2010;29816-821
10. Lehrnbecher T, Phillips R, Alexander S, et al.; International Pediatric Fever and Neutropenia Guideline Panel. Guideline for the management of fever and neutropenia in children with cancer andor undergoing hematopoietic stem-cell transplantation. J Clin Oncol. 2012;304427-4438
11. Singhi S, Deep A. Invasive candidiasis in pediatric intensive care units. Indian J Pediatr. 2009;761033-1044
12. Zaoutis TE, Prasad PA, Localio AR, et al. Risk factors and predictors for candidemia in pediatric intensive care unit patients implications for prevention. Clin Infect Dis. 2010;51e38-e45
13. Pappas PG, Rex JH, Lee J, et al.; NIAID Mycoses Study Group. A prospective observational study of candidemia epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis. 2003;37634-643
14. Horn DL, Neofytos D, Anaissie EJ, et al. Epidemiology and outcomes of candidemia in 2019 patients data from the prospective antifungal therapy alliance registry. Clin Infect Dis. 2009;481695-1703
15. Benetucci A, Tiraboschi IN, Fernández N, et al. [Risk factors associated with multiple-species candidemia]. Rev Argent Microbiol. 2008;4030-36
16. Colombo AL, Nucci M, Park BJ, et al.; Brazilian Network Candidemia Study. Epidemiology of candidemia in Brazil a nationwide sentinel surveillance of candidemia in eleven medical centers. J Clin Microbiol. 2006;442816-2823
17. Cortés JA, Reyes P, Gómez C, et al.; GREBO Group. Fungal bloodstream infections in tertiary care hospitals in Colombia. Rev Iberoam Micol. 2011;2874-78
18. Clinical and Laboratory Standards Institute. Reference Method for the Broth Dilutio Antifungal Susceptibility Testing of Yeasts. Approved Standard. 3rd ed. M27-A3. Wayne, PA Clinical and Laboratory Standars Institute; 2008272
19. Nguyen MH, Clancy CJ, Yu VL, et al. Do in vitro susceptibility data predict the microbiologic response to amphotericin B Results of a prospective study of patients with Candida fungemia. J Infect Dis. 1998;177425-430
20. Pfaller MA, Andes D, Diekema DJ, et al.; CLSI Subcommittee for Antifungal Susceptibility Testing. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updat. 2010;13180-195
21. Blyth CC, Chen SC, Slavin MA, et al.; Australian Candidemia Study. Not just little adults candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients. Pediatrics. 2009;1231360-1368
22. Steinbach WJ, Roilides E, Berman D, et al.; International Pediatric Fungal Network. Results from a prospective, international, epidemiologic study of invasive candidiasis in children and neonates. Pediatr Infect Dis J. 2012;311252-1257
23. Faix RG. Invasive neonatal candidiasis comparison of albicans and parapsilosis infection. Pediatr Infect Dis J. 1992;1188-93
24. Dotis J, Prasad PA, Zaoutis T, et al. Epidemiology, risk factors and outcome of Candida parapsilosis bloodstream infection in children. Pediatr Infect Dis J. 2012;31557-560
25. Zaoutis T. Candidemia in children. Curr Med Res Opin. 2010;261761-1768
26. Pfaller MA, Diekema DJ. Role of sentinel surveillance of candidemia trends in species distribution and antifungal susceptibility. J Clin Microbiol. 2002;403551-3557
27. Kuzucu C, Durmaz R, Otlu B, et al. Species distribution, antifungal susceptibility and clonal relatedness of Candida isolates from patients in neonatal and pediatric intensive care units at a medical center in Turkey. New Microbiol. 2008;31401-408
28. Lee I, Morales KH, Zaoutis TE, et al. Clinical and economic outcomes of decreased fluconazole susceptibility in patients with Candida glabrata bloodstream infections. Am J Infect Control. 2010;38740-745
29. Lee I, Zaoutis TE, Fishman NO, et al. Risk factors for fluconazole resistance in patients with Candida glabrata bloodstream infection potential impact of control group selection on characterizing the association between previous fluconazole use and fluconazole resistance. Am J Infect Control. 2010;38456-460
30. Zaoutis TE, Coffin SE, Chu JH, et al. Risk factors for mortality in children with candidemia. Pediatr Infect Dis J. 2005;24736-739
31. Celebi S, Hacimustafaoglu M, Ozdemir O, et al. Nosocomial candidaemia in children results of a 9-year study. Mycoses. 2008;51248-257
32. Pasqualotto AC, de Moraes AB, Zanini RR, et al. Analysis of independent risk factors for death among pediatric patients with candidemia and a central venous catheter in place. Infect Control Hosp Epidemiol. 2007;28 799-804
33. Ibrahim EH, Sherman G, Ward S, et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest. 2000;118146-155
34. Ben-Abraham R, Keller N, Teodorovitch N, et al. Predictors of adverse outcome from candidal infection in a tertiary care hospital. J Infect. 2004;49317-323
35. Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia a multi-institutional study. Clin Infect Dis. 2006;4325-31
36. Zaoutis T, Walsh TJ. Antifungal therapy for neonatal candidiasis. Curr Opin Infect Dis. 2007;20592-597
37. Hope WW, Castagnola E, Groll AH, et al.; ESCMID Fungal Infection Study Group. ESCMID guideline for the diagnosis and management of Candida diseases 2012 prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect. 2012;18Suppl 738-52